Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008:2008:727505.
doi: 10.1155/2008/727505. Epub 2009 Feb 5.

Antibiotic resistance patterns in invasive group B streptococcal isolates

Mei L Castor  1 , Cynthia G Whitney, Kathryn Como-Sabetti, Richard R Facklam, Patricia Ferrieri, Joanne M Bartkus, Billie A Juni, Paul R Cieslak, Monica M Farley, Nellie B Dumas, Stephanie J Schrag, Ruth Lynfield
Affiliations

Antibiotic resistance patterns in invasive group B streptococcal isolates

Mei L Castor et al. Infect Dis Obstet Gynecol. 2008.

Abstract

Antibiotics are used for both group B streptococcal (GBS) prevention and treatment. Active population-based surveillance for invasive GBS disease was conducted in four states during 1996-2003. Of 3813 case-isolates, 91.0% (3471) were serotyped, 77.1% (2937) had susceptibility testing, and 46.6% (3471) had both. All were sensitive to penicillin, ampicillin, cefazolin, cefotaxime, and vancomycin. Clindamycin and erythromycin resistance was 12.7% and 25.6%, respectively, and associated with serotype V (P < .001). Clindamycin resistance increased from 10.5% to 15.0% (X(2) for trend 12.70; P < .001); inducible clindamycin resistance was associated with the erm genotype. Erythromycin resistance increased from 15.8% to 32.8% (X(2) for trend 55.46; P < .001). While GBS remains susceptible to beta-lactams, resistance to alternative agents such as erythromycin and clindamycin is an increasing concern.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clindamycin and erythromycin resistance among invasive Group B streptococci isolates by year (n = 2 937 isolates).
Figure 2
Figure 2
Clindamycin and erythromycin resistance among invasive Group B streptococci isolates by state (n = 2 937 isolates).
Figure 3
Figure 3
Resistance invasive Group B streptococci isolates among pregnant women and newborns (perinatal) and non-pregnant adults (n = 2 887 isolates).
See this image and copyright information in PMC

References

    1. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. The New England Journal of Medicine. 2000;342(1):15–20. - PubMed
    1. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recommendations and Reports. 2002;51(RR-11):1–22. - PubMed
    1. Fernandez M, Hickman ME, Baker CJ. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrobial Agents and Chemotherapy. 1998;42(6):1517–1519. - PMC - PubMed
    1. Lin F-YC, Azimi PH, Weisman LE, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995–1998. Clinical Infectious Diseases. 2000;31(1):76–79. - PubMed
    1. Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstetrics & Gynecology. 1998;92(2):258–261. - PubMed

Publication types

Substances